Evaluating a new collagen treatment for diabetic foot ulcers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is designed to assess the effectiveness of a purified native type 1 collagen extracellular matrix combined with an antimicrobial agent, compared to standard care alone, in treating chronic diabetic foot ulcers. The study will involve at least 170 participants who will be randomly assigned to receive either standard care, the new collagen treatment with standard care, or another variant of the collagen treatment with standard care. Participants will be monitored weekly for up to 12 weeks to evaluate healing progress, with follow-up visits to confirm complete wound closure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. At least 18 years of age or older.
2. Diagnosis of type 1 or 2 Diabetes mellitus.
3. At enrollment, target ulcer with a minimum surface area of 1.0 cm2
4. The target ulcer must have been present for a minimum of 4 weeks
5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
6. The target ulcer must be Wagner 1 or 2 grade
7. The affected limb must have adequate perfusion confirmed by vascular assessment.
8. If the potential subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment.
10. The potential subject must consent to using the prescribed offloading method for the duration of the study.
11. The potential subject must agree to attend the weekly study visits required by the protocol.
12. The potential subject must be willing and able to participate in the informed consent process.

Exclusion Criteria:

1. The potential subject is known to have a life expectancy of \< 6 months.
2. The potential subject's target ulcer is not secondary to diabetes.
3. The target ulcer is infected or there is cellulitis in the surrounding skin.
4. The target ulcer exposes tendon or bone.
5. There is evidence of osteomyelitis
6. There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
7. The potential subject is receiving immunosuppressants or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing.
8. The potential subject is taking hydroxyurea.
9. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
10. The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
11. The potential subject has a controlled glycated hemoglobin (HbA1c) within 3 months of the initial screening visit.
12. The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
13. Women who are pregnant or considering becoming pregnant within the next 6 months.
14. The potential subject has end stage renal disease requiring dialysis.
15. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.
16. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
17. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
18. The potential subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment.

Where it's running

• Kent State University, College of Podiatric Medicine
  Clevland, Ohio, United States Recruiting

Study contacts

• Study coordinator: Brett Madden
• Email: bmadden@organo.com
• Phone: (781) 575-0775

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BIOxHEAL plus standard care for nonhealing diabetic foot ulcers

  A multicenter study tests whether applying BIOxHEAL, a placental-derived biologic, to stubborn diabetic foot ulcers helps more people heal when added to standard wound care.

  Recruiting Phase 3 Applied Biologics, LLC · Boardman, Ohio · NCT07852338

• Calcaneal Bone Marrow Cells in Foot/Ankle Surgery Patients

  This observational study tests whether routine preoperative blood tests relate to the quality and behavior of mesenchymal stem cells from calcaneal bone marrow in adults undergoing foot or ankle surgery.

  Recruiting Universidade Sao Francisco · Bragança Paulista, São Paulo · NCT07802106

• L-Carnitine as an add-on for healing diabetic foot ulcers

  This study tests whether taking L-Carnitine helps wound healing in adults with diabetic foot ulcers, alongside standard diabetes and wound care.

  Recruiting Phase 2 Ain Shams University · Cairo, Cairo Governorate and 1 other locations · NCT07768228

• THERAVEX Tissue Care Spray Plus for Healing of Skin Wounds and Ulcers

  This observational review tests whether THERAVEX Tissue Care Spray Plus, used with standard wound care, helps heal various skin wounds and chronic ulcers in adults.

  Recruiting Biointelligent Technology Systems SL · Barcelona · NCT07617961

• Pulsating electromagnetic field therapy for diabetic foot ulcers

  This trial tests whether a PEMF device called CRAD ULCER X-01 helps heal chronic diabetic foot ulcers when added to standard wound care.

  Recruiting National Defence University of Malaysia · Kuala Lumpur · NCT07465640

• Transverse tibial bone transport to help heal chronic diabetic foot ulcers

  This study tests a surgical approach called transverse tibial bone transport to see if it can help heal long‑lasting diabetic foot ulcers and prevent limb loss in adults with limited treatment options.

  Recruiting Biodynamik, Inc · Jacksonville, Florida · NCT07444593

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.